Stifel Nicolaus restated their buy rating on shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) in a research report sent to investors on Tuesday. They currently have a $23.00 price target on the stock.
Other equities analysts have also issued research reports about the company. Brean Capital reiterated a buy rating on shares of Concert Pharmaceuticals in a research note on Monday, July 11th. Zacks Investment Research lowered Concert Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, July 11th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $26.43.
Shares of Concert Pharmaceuticals (NASDAQ:CNCE) opened at 10.11 on Tuesday. The stock’s 50 day moving average price is $10.31 and its 200-day moving average price is $11.94. Concert Pharmaceuticals has a 52-week low of $9.47 and a 52-week high of $25.04. The company’s market cap is $224.71 million.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Tuesday, August 9th. The company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.03. Concert Pharmaceuticals had a negative return on equity of 29.09% and a negative net margin of 289.85%. Equities analysts expect that Concert Pharmaceuticals will post ($2.51) EPS for the current year.
Several large investors have recently modified their holdings of the stock. BVF Inc. IL increased its stake in shares of Concert Pharmaceuticals by 23.4% in the first quarter. BVF Inc. IL now owns 2,755,318 shares of the company’s stock worth $37,638,000 after buying an additional 523,304 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Concert Pharmaceuticals by 3.6% in the second quarter. BlackRock Fund Advisors now owns 712,064 shares of the company’s stock worth $7,996,000 after buying an additional 25,029 shares in the last quarter. Ingalls & Snyder LLC acquired a new stake in shares of Concert Pharmaceuticals during the second quarter worth $7,013,000. Numeric Investors LLC increased its stake in shares of Concert Pharmaceuticals by 23.3% in the second quarter. Numeric Investors LLC now owns 618,598 shares of the company’s stock worth $6,947,000 after buying an additional 117,019 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Concert Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 606,359 shares of the company’s stock worth $6,809,000 after buying an additional 23,885 shares in the last quarter. 61.68% of the stock is currently owned by hedge funds and other institutional investors.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.